Cardiac markers can be used effectively for diagnosing, triaging, treating
and monitoring of patients with acute coronary syndromes. Therefore, in acc
ord with the recommendation of the NACB and IFCC, the use of myoglobin and
troponins, especially troponin T (TnT) because of the broader data base, ar
e well-suited to fulfil the needs of management of acute coronary syndromes
. The present paper reviews recent data to evaluate their relevance, especi
ally in deciding the treatment of patients with non-ST elevation acute coro
nary syndromes. Furthermore, economic studies show that the use of even the
more expensive diagnostics is associated with tremendous cost savings due
to more efficient patient management. The use of cardiac markers therefore
represents a valuable tool in the management of these patients. The best co
mbination is that of myoglobin with troponin.